Yamasaki T, Wakabayashi S, Inoue O, Ando K, Kusakabe K, Kawasaki Y, Okamoto S, Taniguchi M
J Invest Dermatol. 1987 Sep;89(3):225-9. doi: 10.1111/1523-1747.ep12470975.
The specific detection of tumors in vivo using a radiolabeled syngeneic monoclonal antibody made by fusion of P3U1 (BALB/c myeloma cells) and C57BL/6 spleen cells primed with syngeneic B16 melanoma cells was investigated by color imaging, autoradiography, and biodistribution. The radiolabeled antimelanoma antibody specifically accumulated only in the tumor lesions, whereas no radioactivity was observed in normal tissues or organs. The distribution patterns of the radioactive antibody in the tumor lesions depended on the sizes of the tumor. Almost the entire region of the small metastatic tumor in lymph nodes was labeled, whereas the radioactive antibody was irregularly localized mainly in the center of the medium-sized tumor. However, only the peripheral region of the large primary tumor was labeled. The highest uptake of radioactivity (tumor:blood ratio) was observed in the small lymph node metastatic tumor lesions rather than in the large primary tumor. Furthermore, high resolution color imaging of B16 melanoma was also obtained by using 125I-labeled monoclonal antibody. Tumor location was specifically visible without subtraction or enhancement methods 3-5 days after injection of the radiolabeled antibody.
利用由P3U1(BALB/c骨髓瘤细胞)与用同基因B16黑色素瘤细胞致敏的C57BL/6脾细胞融合制备的放射性标记同基因单克隆抗体,通过彩色成像、放射自显影和生物分布研究了体内肿瘤的特异性检测。放射性标记的抗黑色素瘤抗体仅在肿瘤病变中特异性积聚,而在正常组织或器官中未观察到放射性。肿瘤病变中放射性抗体的分布模式取决于肿瘤的大小。几乎淋巴结中小转移瘤的整个区域都被标记,而放射性抗体不规则地主要定位在中等大小肿瘤的中心。然而,仅大的原发性肿瘤的周边区域被标记。在小的淋巴结转移瘤病变中观察到最高的放射性摄取(肿瘤:血液比值),而不是在大的原发性肿瘤中。此外,通过使用125I标记的单克隆抗体也获得了B16黑色素瘤的高分辨率彩色成像。在注射放射性标记抗体后3至5天,无需减法或增强方法即可特异性看到肿瘤位置。